

ABSTRACT OF THE DISCLOSURE

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-5 1R1 in a sample using antibodies to IL-1R1 are described.